These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. The Altered States Database: Psychometric data from a systematic literature review. Prugger J; Derdiyok E; Dinkelacker J; Costines C; Schmidt TT Sci Data; 2022 Nov; 9(1):720. PubMed ID: 36418335 [TBL] [Abstract][Full Text] [Related]
67. DNA Authentication and Chemical Analysis of Bradshaw AJ; Backman TA; Ramírez-Cruz V; Forrister DL; Winter JM; Guzmán-Dávalos L; Furci G; Stamets P; Dentinger BTM Appl Environ Microbiol; 2022 Dec; 88(24):e0149822. PubMed ID: 36445079 [TBL] [Abstract][Full Text] [Related]
68. DARK Classics in Chemical Neuroscience: Psilocybin. Geiger HA; Wurst MG; Daniels RN ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917 [TBL] [Abstract][Full Text] [Related]
69. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. Rothberg RL; Azhari N; Haug NA; Dakwar E J Psychopharmacol; 2021 Feb; 35(2):150-158. PubMed ID: 33307947 [TBL] [Abstract][Full Text] [Related]
70. Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Johnson MW; MacLean KA; Reissig CJ; Prisinzano TE; Griffiths RR Drug Alcohol Depend; 2011 May; 115(1-2):150-5. PubMed ID: 21131142 [TBL] [Abstract][Full Text] [Related]
71. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Smigielski L; Scheidegger M; Kometer M; Vollenweider FX Neuroimage; 2019 Aug; 196():207-215. PubMed ID: 30965131 [TBL] [Abstract][Full Text] [Related]
72. Gender differences in the subjective effects of MDMA. Liechti ME; Gamma A; Vollenweider FX Psychopharmacology (Berl); 2001 Mar; 154(2):161-8. PubMed ID: 11314678 [TBL] [Abstract][Full Text] [Related]
73. Effects of psilocybin on time perception and temporal control of behaviour in humans. Wittmann M; Carter O; Hasler F; Cahn BR; Grimberg U; Spring P; Hell D; Flohr H; Vollenweider FX J Psychopharmacol; 2007 Jan; 21(1):50-64. PubMed ID: 16714323 [TBL] [Abstract][Full Text] [Related]
74. Magic Mushrooms - an exploratory look at how mental health professionals feel and think about Psilocybin. Meyer TD; Meir P; Lex C; Soares JC Psychiatry Res; 2022 Oct; 316():114727. PubMed ID: 35878481 [TBL] [Abstract][Full Text] [Related]
76. Poisonings resulting from the ingestion of magic mushrooms in Kraków. Satora L; Goszcz H; Ciszowski K Przegl Lek; 2005; 62(6):394-6. PubMed ID: 16225077 [TBL] [Abstract][Full Text] [Related]
77. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. Kopra EI; Ferris JA; Winstock AR; Young AH; Rucker JJ J Psychopharmacol; 2022 Aug; 36(8):965-973. PubMed ID: 35388724 [TBL] [Abstract][Full Text] [Related]
78. The hidden therapist: evidence for a central role of music in psychedelic therapy. Kaelen M; Giribaldi B; Raine J; Evans L; Timmerman C; Rodriguez N; Roseman L; Feilding A; Nutt D; Carhart-Harris R Psychopharmacology (Berl); 2018 Feb; 235(2):505-519. PubMed ID: 29396616 [TBL] [Abstract][Full Text] [Related]
79. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
80. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Reissig CJ; Carter LP; Johnson MW; Mintzer MZ; Klinedinst MA; Griffiths RR Psychopharmacology (Berl); 2012 Sep; 223(1):1-15. PubMed ID: 22526529 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]